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INTERNATIONAL REGULATION 
• Before 1992, the Genetic Resources (GR) 
were freely accessible and exchanged (with 
consent of the Supplier and with or without contract); 
 
• In 1992 the Convention on Biological 
Diversity (CBD) recognized the sovereign 
rights of States over their natural resources, 
and the access to GR is subject to national 
legislation (Art 15.1). 
 
INTERNATIONAL REGULATION 
• In 2010 the Nagoya Protocol completed the 
CBD. 
• To assure food security and sustainable 
agriculture, the International Treaty on Plant 
Genetic Resources for Food and Agriculture 
was adopted in 2001: 
• 64 species and genus of plants are concerned 
• A Multilateral System of access and benefit-
sharing is established under then management of 
FAO 
 
CONDITIONS FOR ACCES 
• Access to GR shall be  
o subject to the prior informed consent (PIC) of the 
Party providing such resources (country of origin of 
such resources or a Party that has acquired the GR in 
accordance with the CBD); 
o on mutually agreed terms (MAT); 
• Access to Traditional Knowledge (TK) 
associated with GR is subject to the same 
procedures, but with the participation of the 
holders of such knowledge (NP art.7)  
FAIR & EQUITABLE BENEFIT-SHARING 
• Advantages arising from the utilization of GR 
shall be shared in a fair and equitable way 
with the Party providing such resources. 
Such sharing shall be upon mutually agreed 
terms. 
• The advantages arising from the utilization of 
TK associated with GR have to be shared in 
a fair and equitable way with indigenous and 
local communities holding such knowledge 
upon MAT. 
FAIR & EQUITABLE BENEFIT-SHARING 
• The advantages can be monetary or not 
monetary. 
 
• CIRAD promotes non monetary advantages 
(research collaboration, training, transfer of 
technology, co-publication, co-property of the 
results, capacity building…) 
 
• ABS could be a tool to dynamize research 
collaboration. 
PARTIES TO TREATIES 
Country CBD ITPGRFA
Australia 1993-06-18 2012-01-20 yes
Bangladesh 1994-05-03 2011-09-06 yes
Belgium 1996-11-22 2011-09-20 yes
Brazil 1994-02-28 2011-02-02 yes
Cambodia 1995-02-09 2012-02-01 yes
China 1993-01-05 
Denmark 1993-12-21 2011-06-23 yes
France 1994-07-01 2011-09-20 yes
Germany 1993-12-21 2011-06-23 yes
India 1994-02-18 2011-05-11 2012-10-09 yes
Indonesia 1994-08-23 2011-05-11 yes
Italy 1994-04-15 2011-06-23 yes
Japan 1993-05-28 2011-05-11 
Malaysia 1994-06-24 yes
Maldives 1992-11-09 yes
Myanmar 1994-11-25 yes
Netherlands 1994-07-12 2011-06-23 yes
Norway 1993-07-09 2011-05-11 yes
Pakistan 1994-07-26 yes
Papua-New-Guinea 1993-03-16 
Philippines 1993-10-08 yes
Poland 1996-01-18 2011-09-20 yes
Portugal 1993-12-21 2011-09-20 yes
Republic of Korea 1994-10-03 2011-09-20 yes
Democratic People's Republic of Korea 1994-10-26 yes
Lao People's Democratic Republic 1996-09-20 2012-09-26 yes
Singapore 1995-12-21 
Spain 1993-12-21 2011-07-21 yes
Sri Lanka 1994-03-23 
Sweden 1993-12-16 2011-06-23 yes
Thailand 2004-01-29 2012-01-31 only signed
United Kingdom 1994-06-03 2011-06-23 yes
Viet Nam 1994-11-16 
European Union 1993-12-21 2011-06-23 yes
USA only signed only signed
Nagoya:Signed / Party
ADVANTAGES AND RISKS 
• Advantages to adopt ABS in the MTA 
o Legality of the exchanges (security) 
o Traceability 
oCapacity to obtain international Certificate of 
Origin to publish the results, to deposit IPR, to 
develop the results… 
o Share knowledge 
o Ethics  
 
 
 
ADVANTAGES AND RISKS 
• Risks to not adopt ABS 
o Impossibility to develop the results 
oHurts the reputation (affects partners 
confidence) 
o Legal sanctions:  
 fines, 
 imprisonment, 
 obligation to stop the activity or to destroy the GR 
 
 
GLOBAL CONTEXT 
• Research is a long process 
• Results are uncertain 
• Research is based on knowledge sharing 
• Research needs a lot of GR (e.g., in Plants) 
and it’s not easy to determinate the 
participation of each GR in the final product. 
 
 
NATIONAL REGULATION 
• Countries with official free access to GR: 
Switzerland, Germany… 
 
• Countries with regulation: 
o India (with official MTA) 
oBrazil (with validation of CGEN for Brazilian 
GR and publication to the Official Journal for 
exchange with Embrapa) 
 
NATIONAL REGULATION 
• Countries with regulation (continue): 
oThailand: Chapters IV and V of the Plant 
Varieties Protection Act (1999), with 
distinction between research for 
commercial / non commercial purpose  
oEU: Regulation in 2014 (due diligence and 
trusted collections) but application in 
legislation by Member State 
oFrance: law in 2014 
 
 
APPLICATION FOR MTA 
• CIRAD, INRA and IRD 
adopted voluntary rules for 
access and transfer of GR 
that are now a reference in 
France 
• If the GR are included in the 
ITPGRFA, and the utilization 
of the GR is for food and 
agriculture use the SMTA 
 
 
APPLICATION FOR MTA 
• If not, contact the National Focal Point to 
know the national procedures and legislation: 
List of National Focal Points 
 
• Negotiate with the supplier or the recipient 
the conditions of ABS for the utilization of the 
GR or TK and includes the MAT in the MTA. 
 
• Sometimes the MTA has to be validated by 
official service (e.g. Brazil for national GR) 
 
 
 

MTA IS A CONTRACT 
• Agreement between supplier (in most cases 
who has the GR) and the recipient (in most 
cases who will use the GR) 
• A tool for traceability, CBD conformity 
• Clarify the relationship with the possessors of 
GR and TK 
 
 
MTA IS NOT 
• A contract for sale GR or TK 
• A licensing agreement 
• An administrative authorization 
• Valid for Cites (Convention on International 
Trade in Endangered Species of Wild Fauna 
and Flora) or phytosanitary/health  
requirements. 
 
 
 
EXAMPLE OF MTA 
• In case of research collaboration, the MTA is 
paired with the collaboration agreement. 
• If the GR were received with a contract or 
MTA, the new MTA has to contain the 
conditions imposed by the initial MTA 
 
 
 
EXAMPLE OF MTA 
  
TABLE 1. DESIGNATION OF PARTIES 
  
Supplier:  Recipient: 
Registered Office:  Registered Office:  
Represented by:  Represented by:  
In his/her capacity as:  In his/her capacity as: 
  
Acting on its behalf and on behalf of: 
  
Acting on its behalf and on behalf of: 
  
Represented by: Represented by: 
  
In his/her capacity as:  In his/her capacity as: 
  
Legal address: Legal address: 
The Material is supplied by the Supplier to the Recipient under the following conditions: 
EXAMPLE OF MTA 
  
TABLE 2: DESIGNATION OF MATERIAL 
Description of the material (the 
"Material") 
The material may be accompanied by 
information whose transmission and 
use are governed by rules expressed 
in the consortium agreement 
associated with this agreement.  
- Designation of biological material: (common name)_____________ 
Described in annex attached hereto: ______ 
Referenced by number (valid for CRB):____ 
  
- Designation of data and associated information:  
Traditional knowledge 
Confidential information 
Non-confidential information 
  
- Transfer includes access to a database: 
Yes 
No 
  
- Designation of Supplier centre: 
• Name (CRB, etc.): ____________________________ 
• Address: ___________________________________ 
Identification of Material: 
A detailed Annex shall list the 
material if necessary (several entries)  
Collection date: ___________________________________ 
Country of origin: __________________________________ 
Initial Supplier (if from collection): ____________________ 
If IPR (Patent, PVP, Database…), precise reference :______________ 
  
TABLE 3. AUTHORIZED USE 
  
The Material is transferred from the Supplier 
to the Recipient for the sole purpose of 
conducting research as described in the 
collaboration agreement specified:  
Collaboration agreement: 
  
Research Project: 
In order to conduct the project, the  Recipient 
is authorised to use the Material in 
accordance with these defined processes, for 
the duration and in the locations specified 
below. 
Any use of the Material apart from the 
"intended processes" is prohibited and can 
give rise to no claim on the part of the 
Recipient. 
In particular, the generic quality of the 
intended processes shall in no way authorise 
the use of the Material for purposes other 
than those expressly stipulated in the 
collaboration agreement.   
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
Intended processes (specify the authorized operations): 
 
Any use authorized (Material freely accessible) 
1) Genetic modification: Development of new variations within non-human species by means 
of genetic modification techniques, particularly: 
Transfer of a genetic characteristic 
Genetic modification of a microorganism  
Production of recombinant cell lines of attenuated vaccines 
Production of transgenic organism 
Use of nucleic acid-based techniques  
Use of cell fusion outside of the taxonomic family 
2) Biosynthesis 
Use of genetic material as factory for the production of organic compounds 
3) Breeding and Domestication:  
Creation of new varieties, strains or stem cell lines of non-human species, as: 
Breeding of plants, animals or microorganisms (crossing, artificial insemination, cloning…) 
Domestication from wild species 
4) Propagation and culture of the genetic resource in its natural form: 
Cultivation of microorganisms or plants 
Propagation of animals 
Production of plant, animal and microbial products 
Biocontrol. 
5) Characterisation and assessment 
Taxonomic Identification 
Phenotyping 
Genotyping 
Sequencing of genes or genomes  
Determination of the phenotype characteristics for other studies 
Experimental assessment of hereditary characteristics 
Isolation of a compound of genetic material for characterisation  
6) Conservation: Preservation of organisms for the conservation of genetic diversity: 
Collection, botanical gardens, zoos, aquariums, museum… 
Enrichment of natural forest 
7) Other: ___________________________________ 
EXAMPLE OF MTA 
  Duration: 
 
The intended uses of the Material are limited to the 
duration of the agreement to which this MTA is annexed.  
The intended uses of the Material are limited to ___ years 
after the date of signature of this MTA. 
 
In case of extension of the collaboration agreement, this 
MTA will be extended under the same conditions. 
All use of the Material apart from these terms will be 
subject to the prior written agreement of the Supplier. 
The duration limit does not apply to Conservation 
operations. 
 
If transfer of confidential information, the duration of 
confidentiality is ____ years 
Location:  
 
Designation: _____________________________ 
Address: _______________________________ 
Under the responsibility of: ____________________ 
 TABLE 4. SHARING OF ADVANTAGES 
To ensure the sharing of benefits with the country of the Material Supplier in accordance with the CBD, adopted on 
22 May 1992 and entered into force on 29 December 1993, the Nagoya Protocol adopted on October 29, 2010, the 
Parties agree to make every effort to ensure the traceability of materials and compliance with prior informed 
consent of the Supplier of the Material. 
If the Parties were to be led to use the Material or the Results for purposes of commercial exploitation, they shall 
negotiate in good faith the conditions of such exploitation, prior to any commercial use, in a monetary or non-
monetary form, including Intellectual Property Rights sharing. 
For purposes of sharing advantages, the Supplier and the Recipient have agreed to conduct research jointly as 
stipulated in the collaboration agreement to which this MTA is annexed. 
The Recipient agrees to (tick the boxes): 
  
Limit access to the Material and associated information to only the 
partners of the collaboration agreement. 
Inform the Supplier of all later transfers and give the Supplier all 
elements in the Recipient's possession to ensure the traceability of 
the Material. 
Mention the origin of the Material and the identity of the Supplier in 
all publication of results issuing from the Study, except if contrary 
request of the Supplier. 
Transmit the research reports to the Supplier as required in the 
collaboration agreement 
Cite as co-authors the researcher nationals of the country of the 
Initial Supplier who have collaborated in the research.  
Provide access on request by the Initial Supplier to all non-
confidential information obtained or collected by the Recipient.  
Availability of results to the Supplier under privileged conditions. 
The Recipient agrees to respect the specific 
conditions mentioned against, including 
those raised by the Initial Supplier of the 
Material (precise in writing): 
• Commitments made by the initial Supplier: 
_____________________________________________ 
• Specific obligations: (e.g., the Recipient cannot use the Material to 
produce GMO)_________________________________ 
EXAMPLE OF MTA 
  
TABLE 5. TARIFF RATES 
 
The Material is transmitted: 
At no charge 
In exchange for the sum of __________ € as reimbursement 
for preparation and shipping fees. In this case, the Supplier will 
send an invoice detailing payment methods (due date, amount), to the 
address listed on the first page of this document to the attention of the 
Recipient or of another person expressly designated. 
EXAMPLE OF MTA 
General Conditions 
• Definition 
– Study: All research performed completely or in part using the Material 
and within the limits of use described in the collaboration agreement. 
– Material: The Material refers to the description of same in Table 2 and to 
certain elements directly issuing therefrom, such as progeny or 
descendants, mutants, variants and derivatives. It includes the Traditional 
Knowledge and all data associated. 
– Derivatives: Created substances constituting a functional, non-modified 
sub-unit (e.g., purified or fractionated parts of the original material, etc.)  
– Product: Any new substance created through the modification of the 
original Material by human intervention.  
– Result: Any product or knowledge obtained from the authorized use of 
the Material. 
EXAMPLE OF MTA 
• Use of the Material 
– The Material is transferred from the Supplier to the Recipient for the 
sole purpose of use in conformity with the declarations executed in 
Table 3. In case of uses not in conformity with those authorised, the 
Recipient shall return to the Supplier the resulting Products as well as 
any associated information, and may claim no right nor profit therefrom 
in any manner whatsoever. 
– The Material may not be protected by any intellectual property rights 
on the received form whatsoever by the Recipient or any third party.  
• Later Transfer of Material by the Recipient: 
yes (conditions) or no 
• Rights and obligations of the Recipient 
• Warranties and Obligations of the Supplier 
• Confidentiality (next slide) 
• Term and Termination 
• Applicable Law and Jurisdiction 
 
EXAMPLE OF MTA 
• Confidentiality  
With Research Collaboration: detailed in the Collaboration Agreement 
Without Research Collaboration: 
In case of transfer of confidential information, the Recipient agrees, unless otherwise consented in writing by the 
Supplier, to do the following: 
• consider the Confidential Information strictly confidential and treat it with the same degree of protection it grants its own 
Confidential Information;  
• not use the Confidential Information for purposes other than performance of the Research Project; 
• not disclose the Confidential Information to third parties; 
• transmit the Confidential Information under its responsibility only to employees or subcontractors who are directly concerned 
by the Research Project, themselves subject to contractual or statutory confidentiality. 
Is not considered as confidential the information for which the Recipient that has received it can prove that: 
• it belonged to the public domain at the time it was communicated; or 
• it subsequently entered the public domain otherwise than by failure to meet the present obligation of confidentiality; or 
• the Recipient held it prior to its being communicated, it being possible to prove this prior holding through the existence of 
appropriate documents in its files; or 
• it was developed independently by one or more members of the personnel of the Recipient not having had access to said 
information; or 
• the Recipient received it freely from a third party which is authorized to disclose it; or 
• it is bound by the law or regulations to communicate said information or by an injunction of any competent administrative or 
judicial authority. 
However, the Supplier cannot prevent publication of the Results, the filing of industrial property rights and 
exploitation of the Results, except for serious and legitimate reasons. 
 
EXAMPLE OF MTA 
EXAMPLE OF MTA 
Signed and delivered in ___________, in __ original copies. 
  
On behalf of the Supplier  On behalf of the Recipient 
Title:      Title: 
Name:    Name: 
Date:     Date:  
This MTA and the collaboration agreement to which it is attached 
are inseparable. Regarding the sharing of results related to 
utilisation of the Material, the publications resulting from it, or the 
confidentiality related to transfer of the Material and its associated 
information, the terms of the abovementioned collaboration 
agreement are directly applicable to this MTA. 
MTA & IPR 
• MTA respects the IPR on the Material 
 
• Ownership and IPR on results: 
– Held by the Collaboration Agreement: 
• Co-ownership, common IPR, co-development and co-publication justified 
only if collaboration. The parties have to participate to obtain the results; 
• But, sharing of advantages is essential in any cases. 
 
– If there is no collaboration, IPR on results depends on the importance 
of the material to obtain the results:  
• If the material is fundamental to obtain the results co-ownership and co-
IPR could be legitimated but not automatically 
• If the material is ordinary or another Institution could transfer the same 
material, co-ownership, co-IPR are not justified 
• In any case, if there is no collaboration, the co-publication is not allowed. 
 
 
 
 
CONCLUSION 
• MTA is: 
– A response to legal obligation in more and more 
countries 
– Important for security of access and exchanges (legally, 
for development of results, publications…) 
– A tool for research collaboration 
– A tool for confidence (with partners, Governments, 
official services, branding…) 
– An element of the Development by the Research 
 
 
 
 
 
 
Thanks a lot 
for 
your attention 
